 Karen Gieseker
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 2 | 2021 | 28 | 0.920 |
Why?
| | Gonorrhea | 2 | 2021 | 62 | 0.860 |
Why?
| | Streptococcus pyogenes | 2 | 2003 | 45 | 0.390 |
Why?
| | Antigens, Bacterial | 2 | 2003 | 127 | 0.380 |
Why?
| | Hazardous Substances | 1 | 2011 | 18 | 0.350 |
Why?
| | Drug Therapy | 1 | 2011 | 85 | 0.340 |
Why?
| | Occupational Exposure | 1 | 2011 | 342 | 0.260 |
Why?
| | Multiple Sclerosis | 2 | 2011 | 456 | 0.250 |
Why?
| | Pharyngitis | 2 | 2003 | 26 | 0.250 |
Why?
| | Community Health Workers | 2 | 2024 | 62 | 0.220 |
Why?
| | Streptococcal Infections | 2 | 2003 | 149 | 0.220 |
Why?
| | Bacterial Typing Techniques | 1 | 2003 | 44 | 0.200 |
Why?
| | Air Pollutants | 1 | 2008 | 430 | 0.200 |
Why?
| | Nasopharynx | 1 | 2002 | 73 | 0.190 |
Why?
| | Culture Media | 1 | 2002 | 163 | 0.190 |
Why?
| | Ceftriaxone | 1 | 2021 | 22 | 0.180 |
Why?
| | Azithromycin | 1 | 2021 | 98 | 0.170 |
Why?
| | Demography | 1 | 2021 | 290 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 1 | 2021 | 342 | 0.170 |
Why?
| | Drug Resistance, Bacterial | 1 | 2021 | 184 | 0.170 |
Why?
| | Health Behavior | 1 | 2024 | 775 | 0.140 |
Why?
| | Epidemiologic Research Design | 1 | 1997 | 28 | 0.140 |
Why?
| | beta-Endorphin | 2 | 1994 | 8 | 0.130 |
Why?
| | Pituitary Gland | 2 | 1994 | 148 | 0.120 |
Why?
| | Dietary Fats | 1 | 1997 | 304 | 0.120 |
Why?
| | Fatty Acids | 1 | 1997 | 447 | 0.110 |
Why?
| | Depression | 1 | 2024 | 1443 | 0.110 |
Why?
| | Anti-Bacterial Agents | 3 | 2021 | 1783 | 0.100 |
Why?
| | Exercise | 1 | 2024 | 2074 | 0.090 |
Why?
| | Pregnancy, Ectopic | 1 | 2011 | 54 | 0.090 |
Why?
| | Health Promotion | 2 | 2024 | 754 | 0.080 |
Why?
| | Obesity | 1 | 2024 | 3028 | 0.080 |
Why?
| | Female | 11 | 2024 | 73060 | 0.080 |
Why?
| | Operating Rooms | 1 | 2011 | 122 | 0.080 |
Why?
| | Maternal Health Services | 1 | 2010 | 103 | 0.070 |
Why?
| | Georgia | 1 | 2008 | 86 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2003 | 1911 | 0.070 |
Why?
| | Humans | 13 | 2024 | 136966 | 0.070 |
Why?
| | Male | 9 | 2021 | 67426 | 0.060 |
Why?
| | Aflatoxins | 1 | 2005 | 3 | 0.060 |
Why?
| | Food Contamination | 1 | 2005 | 51 | 0.060 |
Why?
| | Zea mays | 1 | 2005 | 45 | 0.060 |
Why?
| | United States | 2 | 2021 | 14894 | 0.060 |
Why?
| | Policy Making | 1 | 2005 | 98 | 0.060 |
Why?
| | Foodborne Diseases | 1 | 2005 | 61 | 0.060 |
Why?
| | Utah | 1 | 2024 | 63 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2008 | 573 | 0.050 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2003 | 37 | 0.050 |
Why?
| | Immunoassay | 1 | 2003 | 113 | 0.050 |
Why?
| | Colony Count, Microbial | 1 | 2002 | 119 | 0.050 |
Why?
| | Neoplasms | 1 | 1997 | 2704 | 0.050 |
Why?
| | Meningitis, Viral | 1 | 2002 | 21 | 0.050 |
Why?
| | Bacteriological Techniques | 1 | 2002 | 69 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2005 | 421 | 0.050 |
Why?
| | Hospital Charges | 1 | 2002 | 42 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1155 | 0.050 |
Why?
| | Probability | 1 | 2002 | 304 | 0.050 |
Why?
| | Specimen Handling | 1 | 2003 | 181 | 0.050 |
Why?
| | Enterovirus | 1 | 2002 | 86 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 733 | 0.040 |
Why?
| | Appendicitis | 1 | 2003 | 136 | 0.040 |
Why?
| | Pregnancy | 2 | 2011 | 6725 | 0.040 |
Why?
| | Mentoring | 1 | 2024 | 154 | 0.040 |
Why?
| | Public Health | 1 | 2005 | 588 | 0.040 |
Why?
| | Sexual Partners | 1 | 2021 | 188 | 0.040 |
Why?
| | DNA, Viral | 1 | 2002 | 368 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 509 | 0.040 |
Why?
| | Enterovirus Infections | 1 | 2002 | 177 | 0.040 |
Why?
| | Societies, Medical | 1 | 2003 | 809 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2008 | 5802 | 0.040 |
Why?
| | Nutritional Physiological Phenomena | 1 | 1997 | 55 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2021 | 484 | 0.030 |
Why?
| | Logistic Models | 1 | 2002 | 2071 | 0.030 |
Why?
| | Infant | 4 | 2005 | 9403 | 0.030 |
Why?
| | Bufo marinus | 2 | 1994 | 4 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5522 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 804 | 0.030 |
Why?
| | Child, Preschool | 4 | 2005 | 10970 | 0.030 |
Why?
| | Time Factors | 2 | 2002 | 6787 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 1994 | 577 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2003 | 1292 | 0.030 |
Why?
| | Endopeptidases | 1 | 1994 | 92 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1993 | 169 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 1993 | 129 | 0.030 |
Why?
| | Child | 4 | 2005 | 21776 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 1994 | 462 | 0.020 |
Why?
| | Prospective Studies | 1 | 2003 | 7511 | 0.020 |
Why?
| | Tanzania | 1 | 2010 | 58 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 13202 | 0.020 |
Why?
| | Length of Stay | 2 | 2003 | 1204 | 0.020 |
Why?
| | Health Education | 1 | 2010 | 355 | 0.020 |
Why?
| | Population Surveillance | 1 | 2010 | 484 | 0.020 |
Why?
| | DNA Adducts | 1 | 2005 | 17 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2005 | 24 | 0.020 |
Why?
| | Food Handling | 1 | 2005 | 61 | 0.010 |
Why?
| | Middle Aged | 2 | 2024 | 33247 | 0.010 |
Why?
| | Program Evaluation | 1 | 2010 | 901 | 0.010 |
Why?
| | Kenya | 1 | 2005 | 118 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2005 | 168 | 0.010 |
Why?
| | Adult | 2 | 2024 | 37693 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2010 | 780 | 0.010 |
Why?
| | Emergency Medical Services | 1 | 2010 | 553 | 0.010 |
Why?
| | Risk Factors | 1 | 1997 | 10368 | 0.010 |
Why?
| | Rupture, Spontaneous | 1 | 2003 | 17 | 0.010 |
Why?
| | Regression Analysis | 1 | 2005 | 1001 | 0.010 |
Why?
| | Survival Analysis | 1 | 2005 | 1293 | 0.010 |
Why?
| | Appendectomy | 1 | 2003 | 86 | 0.010 |
Why?
| | Hospital Costs | 1 | 2003 | 115 | 0.010 |
Why?
| | Health Policy | 1 | 2005 | 390 | 0.010 |
Why?
| | Drug Costs | 1 | 2003 | 105 | 0.010 |
Why?
| | Health Resources | 1 | 2003 | 119 | 0.010 |
Why?
| | Cerebrospinal Fluid | 1 | 2002 | 91 | 0.010 |
Why?
| | Patient Admission | 1 | 2003 | 196 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2003 | 327 | 0.010 |
Why?
| | Adolescent | 3 | 2005 | 21467 | 0.010 |
Why?
| | Acute Disease | 1 | 2003 | 995 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1218 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2002 | 1049 | 0.010 |
Why?
| | Laparoscopy | 1 | 2003 | 450 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2005 | 3548 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2003 | 10715 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1474 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 3462 | 0.010 |
Why?
| | Animals | 2 | 1994 | 36934 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1994 | 55 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 330 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1994 | 392 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 384 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 6053 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2143 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1994 | 2903 | 0.000 |
Why?
| | Aged | 1 | 2005 | 23843 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2002 | 15619 | 0.000 |
Why?
|
|
Gieseker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|